NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects

CompletedPhase 4

Sponsor: Laval University

Conditions: Migraine

Interventions: Clopidogrel

Countries: Canada

The addition of clopidogrel on top of aspirin may reduce the occurrence of new-onset migraine headache episodes following transcatheter ASD closure.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patients ≥ 18 year old undergoing transcatheter ASD closure with the Amplatzer Septal Occluder device (AGA medical Corp., MN, USA).
* Female subjects must be post-menopausal, surgically sterile, or using an effective method of birth control.
* Signed an informed consent document.

Exclusion Criteria:

* Allergy or intolerance to any of the antithrombotic drugs (aspirin, clopidogrel) used in the study.
* Need for anticoagulation therapy.
* Use of ASD closure devices other than the Amplatzer Septal Occluder device.
* History of migraine headaches (based on migraine headache questionnaire).
* Refusal to sign the informed consent.
* Pregnancy or breast-feeding or planning to become pregnant during the study.
* Previous stroke.

Locations (1)

Québec, Canada